A randomized trial (CCTG MA.32 phase 3 trial) using adjuvant metformin failed to show overall benefit regarding relapse and survival as reported at 2021 San Antonio Breast Cancer Symposium, but a positive signal could be detected for HER2-positive patients. Here, ERBB2 is linked to breast carcinoma.